Company profile: Destiny Pharma
1.1 - Company Overview
Company description
- Provider of novel antimicrobial products in clinical development, including XF-73 Nasal for prevention of post-surgical Staphylococcal infections (preparing for Phase 3), NTCD-M3 to prevent recurring C. difficile gut infections (preparing for Phase 3), XF-73 Dermal for skin infections, an XF platform with a rapid mechanism that reduces resistance, and biotherapeutic programs for infection prevention.
Products and services
- NTCD-M3: A Phase 3-ready, non-toxigenic Clostridioides difficile strain M3 developed to prevent recurring C. difficile gut infections, currently preparing for Phase 3 clinical trials
- XF-73 Nasal: A clinical-stage nasal antimicrobial compound created to prevent post-surgical Staphylococcal infections, with an innovative mechanism distinct from existing antibiotics, currently preparing for Phase 3 studies
- XF Platform: A rapid-acting antimicrobial drug platform engineered with a fundamentally different mechanism that reduces bacterial resistance likelihood, offering potential advantages in controlling infections across the XF compound series
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Destiny Pharma
Ausper Bio
HQ: China
Website
- Description: Provider of biotechnology therapies developing ASO and oligonucleotide-conjugate drugs for chronic hepatitis B and other major infectious diseases, featuring AHB-137 (Phase I) targeting a conserved HBV mRNA region with potential HBsAg reduction and favorable safety, and Med-Oligo platforms that enhance ASO potency and safety, combining small molecule and antibody expertise.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Ausper Bio company profile →
Normax Biomed
HQ: Ireland
Website
- Description: Provider of mRNA vaccine R&D and manufacturing for infectious diseases such as tuberculosis and HIV. Delivers Vax Factory, a modular solution for rapid, scalable production; leads the mRNA UCV Consortium; and runs GOAL 2050 to end TB and HIV transmission via mRNA vaccines, affordable treatments, and education, supporting the SDG for good health & well being.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Normax Biomed company profile →
Mucosis
HQ: The Netherlands
Website
- Description: Provider of clinical-stage mucosal vaccines delivered needle-free via the nose or mouth, including SynGEM®, an intranasal vaccine candidate to prevent respiratory syncytial virus infection.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Mucosis company profile →
Melinta
HQ: United States
Website
- Description: Provider of antibiotics, developing and commercializing antibiotics to overcome drug-resistant infections.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Melinta company profile →
Lumora
HQ: United Kingdom
Website
- Description: Provider of workflow-based molecular diagnostics solutions that simplify clinical diagnostics, industrial microbiology, and sample preparation, based on its proprietary BART Technology platform; developing an integrated testing station for gastrointestinal (GI).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Lumora company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Destiny Pharma
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Destiny Pharma
2.2 - Growth funds investing in similar companies to Destiny Pharma
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Destiny Pharma
4.2 - Public trading comparable groups for Destiny Pharma
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →